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The reduced availability of nitric oxide (NO) is associated with cardiovascular diseases. Therefore, NO
donors such as organic nitrates are useful for the treatment of these disorders. The 2-nitrate-1,3-
dibuthoxypropan (NDBP) is an organic nitrate synthesized from glycerin, which the pharmacological
effects have not been investigated. In this study we evaluated the vasorelaxant effect induced by NDBP
in superior mesenteric artery from rats. In phenylephrine pre-contracted artery rings, NDBP (108–
104 M) elicited concentration-dependent and endothelium-independent relaxation, which were
attenuated by hydroxocobalamin-HDX (30 mM), a NO extracellular scavenger, and 1-H-[1,2,4] oxadia-
zolo [4,3-a] quinoxalin-1-one-ODQ (10 mM), an inhibitor of soluble guanylyl cyclase (sGC). In addition,
the NDBP-induced relaxation was reduced by non-selective Kþ channels blocker KCl (20 mM) or
selective Kþ channels blockers such as tetraethylammonium-TEA (BKCa, 1 mM), charybdotoxin-ChTX
(BKCa, 100 nM), glibenclamide (KATP, 1 mM) and 4-aminopyridine-4-AP (KV, 1 mM). In preparations with
ODQ (10 mM) plus TEA (1 mM), the response was virtually abolished. In rat smooth muscle cells culture,
NDBP (106–104 M) caused concentration-dependent increases in NO levels. These ﬁndings suggest
that NDBP causes vasorelaxation through NO generation and activation of the sCG/cGMP/PKG pathway.
& 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The nitric oxide (NO) is an important molecule in the modula-
tion of cardiovascular function (Shapoval, 2004). One of its actions
consists of vascular tone regulation by direct vascular smooth
muscle cells relaxation via activation of soluble guanylyl cyclase
(Schmitt and Dirsch, 2009). The vascular tone in turn, is one of the
major determinants of blood ﬂow resistance, playing important
role in blood pressure regulation (Jackson, 2000). Therefore,
dysregulation of the vascular tone contributes to the generation
and maintenance of some cardiovascular diseases, which have
been linked to decreased NO availability (Nassem, 2005).
The mechanisms underlying the vasorelaxation elicited by NO
involve activation of guanylate cyclase (sGC), increasing intracel-
lular levels of cyclic guanosine monophosphate (cGMP) (Archer
et al., 1994), resulting in activation of protein kinase G (PKG),
which is an enzyme responsible for the phosphorylationcional de Desenvolvimento
18/2011-4.
.
).
lsevier OA license.of several proteins involved on vasorelaxation (McDonald and
Murad, 1996). Among the targets for PKG, the vascular smooth
muscle Kþ channels signiﬁcantly contribute to vascular tone
regulation and their opening results in cell hyperpolarization or
repolarization due to Kþ efﬂux, followed by subsequent closing of
voltage-dependent Ca2þ channels, decreasing the intracellular
level of Ca2þ leading to vasodilatation (Archer et al., 1994;
Gurney, 1994; Haddy et al., 2006; Lovren and Triggle, 1998;
Sand et al., 2006). Nevertheless, several studies documented that
NO may act by a cGMP-independent mechanism, through direct
activation of Kþ channels also resulting in vascular relaxation
(Bolotina et al. 1994; Mistry and Garland, 1998; Plane et al.,
1996).
Due to the role of NO in vascular tone regulation, a decrease in
its bioavailability is associated with several cardiovascular dis-
eases (Nassem, 2005), such as hypertension and coronary disease.
In this context, potential NO donors, that mimic the role of
endogenous NO when applied to biological systems, have pre-
sented beneﬁcial effects on these disorders. The organic nitrova-
sodilators, such as glyceril trinitrate and amyl nitrite, currently
used in clinical practice, induce vascular smooth muscle cells
relaxation, improving blood supply and thereby presenting a
beneﬁcial effect against angina pectoris, pulmonary hypertension,
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likely to NO release (Goyal et al., 2006; Yurtseven et al., 2003).
Considering the importance of these compounds in treating
cardiovascular diseases, the efforts employed to the discovery
and synthesis of novel NO donors, including organic nitrates, from
different sources is justiﬁed.
Therefore, the aim of the present study was to evaluate the
vasorelaxant effect of a glycerin-derived newly synthesized organic
nitrate, the 2-nitrate-1,3-dibuthoxypropan (NDBP) (Fig. 1), on vas-
cular smooth muscle cells of rats and to unravel the underlying
mechanisms involved in its vasorelaxant effect.2. Material and methods
2.1. Synthesis of the 2-nitrate-1,3-dibuthoxypropan (NDBP)
According to Santos (2009), NDBP was synthesized at the
Department of Chemistry at the Federal University of Paraiba.
Its synthesis was divided in three steps: 1. Obtaining haloydrin:
haloydrin(1,3-dichlorine-propan-2-ol) was obtained by reaction
between glycerin and hydrochloric acid (HCl) dry in a reaction
with 70% yield (Fig. 2A). 2. Obtaining 1,3-diether-propan-2-ol:ha-
loydrin was added dropwise into a solution of sodium alkoxide,
this obtained by reaction between metallic sodium and anhy-
drous alcohol. As a product we obtained 1,3-diether-propan-2-olFig. 1. Structural formula of NDBP.
Fig. 2. Synthetic route of 2-nitrateand sodium chloride, according to Fig. 2B. and 3. Obtaining of
2-nitrate-1,3-dibuthoxypropan: by nitration of 1,3-diether-propan-
2-ol was originated a compound called 2-nitrate-1,3-dibuthox-
ypropan (NDBP) (Fig. 2C).2.2. Preparation of the NDBP
The NDBP was dissolved in a mixture of distilled water and
chremophor and diluted to the desired concentrations with
distilled water. In functional studies, the ﬁnal concentration of
cremophor never exceeded 0.01% in the bath and had no effect
when tested in control preparations (data not shown).2.3. Animals
Male Wistar rats (250–300 g), housed under controlled condi-
tions of temperature (2171 1C) and lighting cycle (lights on:
06:00–18:00 h) with water and food (Labinas, PURINA, Brazil) ad
libitum, were used in all experiments. Experiments were con-
ducted in accordance with the Institutional Animal Care and Use
Committee of the Biotechnology Center–Federal University of
Paraı´ba (CEPA 0310X09).2.4. Drugs
Phenylephrine chloride, acetylcholine chloride, 1-H-[1,2,4]
oxadiazolo–[4,3-a] quinoxalin-1-one (ODQ), tetraethylammonium-
chloride (TEA), charybdotoxin (ChTX), 4-aminopyridine (4-AP) and
glibenclamide were obtained from Sigma-Aldrich (S~ao Paulo, SP,
Brazil). Hydroxocobalamin (HDX) was obtained from Bristol-Myers
Squibb (S~ao Paulo, SP, Brasil), and Diaminoﬂuorescein diacetate
(DAF-2 DA) from Calbiochems (S~ao Paulo, SP, Brasil). ODQ and
glibenclamide were dissolved in DMSO. All other compounds were
dissolved in distilled water.
The composition of the Tyrode’s solution used was (mM): NaCl,
158.3; KCl, 4.0; CaCl2, 2.0; MgCl2, 1.05; NaH2PO4, 0.42; NaHCO3,
10.0; and glucose, 5.6. In depolarizing Tyrode’s solution with KCl
(20 mM), the concentration of Naþ was isosmotically adjusted.-1,3-dibuthoxypropan (NDBP).
Fig. 3. Concentration-response curves of NDBP (108–104) in rat mesenteric
artery rings (n¼6). The vasorelaxant effect is expressed as a percentage of
relaxation in phenylephrine-induced contraction. Intact endothelium (K),
Denuded endothelium (J).
Fig. 4. Effect of hydroxocobalamin (30 mM) (n¼6) (~) and ODQ (10 mM) (n¼7)
(’) on NDBP-induced relaxation in phenylephrine-contracted mesenteric artery
rings (n¼6). Values are means7S.E.M. *Po0.05 using two way ANOVA followed
by Bonferroni’s post test.
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After euthanasia, the superior mesenteric artery was isolated,
placed in Tyrode’s solution and dissected in order to make it free
of adhering tissue. In endothelium-denuded experiments,
endothelium was removed by rubbing the intimal surface of the
vessels. Rings with 1–2 mm were obtained and placed in physio-
logical Tyrode’s solution, maintained to 37 1C, gassed with carbo-
genic mixture (95% O2 and 5% CO2) and kept at pH 7.4. All
preparations were stabilized under a resting tension of 0.75 g for
1 h. The solution was replaced every 15 min in order to prevent
the accumulation of metabolites. The force of contraction was
isometrically recorded by a force transducer (Miobath-4, WPI,
Sarasota, FL, USA) coupled to an ampliﬁer-recorder (Miobath-4,
WPI, Sarasota, FL, USA) and to a computer equipped with an
analog-to-digital converter board as described earlier.
The presence of functional endothelium was assessed by the
ability of acetylcholine (10 mM) to induce more than 80% relaxation
of vessels pre-contracted with phenylephrine (10 mM). Less than
10% of relaxation to acetylcholine was taken as evidence that the
vessel segments were functionally denuded of endothelium. The
preparations were exposed to: (a) hydroxycobalamin (30 mM), a
NO scavenger (Kruszyna et al., 1998); (b) ODQ (10 mM), a soluble
guanylyl cyclase inhibitor (Garthwaite et al., 1995); (c) KCl (20 mM),
a modulator of potassium efﬂux (Campbell et al., 1996); and (d)
selective blockers for large condutance calcium-sensitive potassium
channel (TEA, 1 mM and ChTX, 100 nM), ATP-sensitive potassium
channel (glibenclamide, 1 mM), and voltage-operated potassium
channel (4-AP, 1 mM) (Adaramoye and Medeiros, 2009; Berg, 2002;
Huang and Kwok, 1997; Mombouli and Vanhoutte, 1997). These
inhibitors were added 30 min before the application of phenylephr-
ine. In the tonic phase of the contraction, NDBP (108–104 M) was
cumulatively added to preparations until a maximum response to the
drug accumulation was observed as indicated by a plateau response
(approximately 3–5min). Inhibition was calculated by comparing the
response elicited by NDBP in the absence and presence of inhibitors
or antagonists in the preparation.
2.6. Measurements of intracellular NO production in aortic rat
smooth muscle cells culture
Rat vascular smooth muscular cells (VSMC) line were grown in
24-well plates on the F12 medium and supplemented with 10%
fetal bovine serum and antibiotics (penicillin and streptomycin)
as previous described (Kojima et al., 1998). Samples were then
washed twice with phosphate-buffered saline containing bovine
serum albumin and analyzed with 10.000 cells per sample by ﬂow
cytometry using the FACSCalibur equipment (Becton Dickinson, San
Jose, CA, USA). Bioavailability of NO in VSMC line was quantiﬁed by
exposing the biological samples to NDBP (106, 3105 M, 104 M)
or to glyceril trinitrate (GTN), the positive control, for 30 min after
pre-incubation with DAF-2 DA (10mM) for 5 min at 37 1C. The DAF-2
DA is a ﬂuorescent indicator that enables the direct detection of NO
under physiological conditions by ﬂow cytometry (Navarro-Antolin
and Lamas, 2001). We have detected the concentration of NO release
without stimulation (basal ﬂuorescence) and changes in intracellular
NO concentration after treatments with NDBP or GTNwere expressed
as ratio between ﬂuorescence after treatments (F) and basal ﬂuores-
cence (F0): F/F0. Treatments were performed in biological triplicate.
Values were expressed as mean7S.E.M. and analyzed by a WinMDI
software version 2.9.
2.7. Statistical analysis
Data were expressed as mean7S.E.M. The maximum effect
was considered as the maximum response to phenylephrine(10 mM) for the highest concentration used. Statistical analyses
were performed by Student t-test, two-way ANOVA followed by
Bonferroni’s post-test, or one-way ANOVA with Tukey’s post-test
when appropriate, using a GraphPad Prism& software version 5.0
(GraphPad Software Inc., La Jolla, CA, USA). Signiﬁcance was
considered when Po0.05.3. Results
3.1. Effect induced by NDBP in arteries pre-contracted with
phenylephrine
Administration of glycerin-derived organic nitrate, NDBP
(108–104 M), produced concentration-dependent vasorelaxa-
tion in phenylephrine pre-contracted superior mesenteric artery
rings isolated from rats in the presence of functional endothelium
(pD2¼5.8570.10;ME¼89.573.4%, n¼6). In addition, removal of
endothelium did not alter the response induced by the compound
(pD2¼5.9970.06; ME¼105.472.7%, n¼6) (Fig. 3).
3.2. Effect of the NO scavenger and soluble guanylyl-cyclase
inhibitor on the relaxation induced by NDBP
In endothelium denuded mesenteric rings pre-treated with
hydroxocobalamin (30 mM), NDBP-induced relaxation was signif-
icantly attenuated with reduction of pD2 values, from 5.997
0.06–5.3970.12, Po0.05, n¼6. The maximum effect (ME) also
Fig. 5. A. Effect of KCl 20 mM (~) on NDBP-induced relaxation in phenylephrine-contracted mesenteric artery rings (n¼9); Effects of TEA 1 mM (~) in B; ChTX 100 nM
(~) in C; 4-AP 1 mM (~) in D, and glibenclamide 1 mM (~) in E on NDBP-induced relaxation in phenylephrine-contracted mesenteric artery rings (n¼6). Values are
means7S.E.M. *Po0.05 using two way ANOVA followed by Bonferroni’s post test.
Fig. 6. Effect of ODQ (~) (10 mM) (n¼7) and ODQ (10 mM) plus TEA (1 mM) (n¼6)
(B) on NDBP-induced relaxation in phenylephrine-contracted mesenteric artery
rings (n¼6). Values are means7S.E.M. *Po0.05 using two way ANOVA followed
by Bonferroni’s post test.
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addition, in the presence of ODQ (10 mM), the response evoked for
NDBP was almost abolished (ME: from 105.472.7% to 15.27
9.2%, Po0.05) (Fig. 4).
3.3. Effect of Kþ channels blockers and the combination of ODQ and
Kþ channel blocker on the relaxation induced by the NDBP
Pretreatment with KCl (20 mM), a Kþ efﬂux modulator,
signiﬁcantly attenuated the vasorelaxant response of NDBP. As a
result, KCl (20 mM) shifted to the right the concentration-
response curve (pD2: 5.147 0.13, n¼9, Po0.05) and reduced
the maximum effect to 70.6715.1% (Fig. 5A).
Last but not the least, the vasorelaxant responses induced
by increasing concentrations of NDBP (108–104 M) were
also signiﬁcantly rightward shifted, when incubated with TEA
(BKCa blocker, 1 mM) (pD2¼5.5870.16, p¼0.045, n¼6) and
4-aminopyridine (KV blocker, 1 mM) (pD2¼5.5970.05, p¼0.48,
n¼6) (Fig. 5B e 5E). The ChTX (BKCa blocker, 100 nM) was able to
attenuate the NDBP-induced vasodilatation reducing the pD2
values to 5.3570.07, Po0.05, n¼6 and maximum effect to
76.7674.67%, Po0.05, n¼6, as showed in Fig. 5C. The same
was found in the presence of glibenclamide (KATP blocker, 1 mM)(pD2¼5.4370.08, Po0.05, n¼6; ME¼78.2874.67%, Po0.05,
n¼6) (Fig. 5D). Moreover, the combination of TEA (1 mM) and
ODQ (10 mM), produced the same effect as when ODQ was
administered alone, eliciting the maximum effect of 6.373.6%
and 15.279.2%, respectively, n¼6 (Fig. 6).
Fig. 7. NO generation in vascular smooth muscle cells (106/ml) estimated using
Diaminoﬂuorescein diacetate (DAF-2DA). Bar graph showing the effects of glyceryl
trinitrate (GTN, 106104 M) as positive control and NDBP (106–104 M) on
NO levels expressed as relative ﬂuorescence in aortic rat vascular smooth muscle
cells. These data are representative of 3 separate experiments in triplicate, the
production baseline was zeroed and the difference was plotted as percentage of
ﬂuorescence in different treatments. Po0.05 * versus basal ﬂuorescence; # versus
NDBP (106 M) and NDBP (3105 M). Values are shown as mean7S.E.M.
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with NDBP
Based on our observations in isolated vessel preparations, we
quantiﬁed the bioavailability of NO using ﬂow cytometry analysis by
quantifying the relative ﬂuorescent using DAF2-DA, which increases
in proportion to the amount of NO released in the vascular smooth
muscle cells. Therefore, in vascular smooth muscle cells line, NDBP
(106 M, 3105 M and 104 M) was able to increase the relative
ﬂuorescence (22.071.2; 37.974.0; 75.879.5; D% ﬂuorescence,
n¼3), suggesting the production of NO in the culture medium
compared to its control (Fig. 7), corroborating the results obtained in
functional studies. There was no statistical difference between NO
production of NDBP and to that elucidated by GTN (NDBP, 106 M:
22.071,2 versus GTN, 106 M: 42.5711.3; and NDBP, 104 M:
75.879.5 versus GTN, 104 M: 105.7712.9).4. Discussion
The major ﬁnding of this work was that the organic nitrate
NDBP, induces vasorelaxation in rat superior mesenteric artery
rings through NO release and subsequently activation of the
NO-GMPc pathway and Kþ channels activation.
Relaxing substances synthesized and released by endothelial
layer are involved in the mechanisms of relaxation in vascular
smooth muscle cells. Among those substances is NO, the main
vasodilator produced by endothelium. In addition, relaxation can
also be induced by exogenous NO, obtained from NO donors.
These compounds are able to relax the vessels in a endothelium-
independent fashion. In this context, our data pointed out that
NDBP relaxed the pre-contracted rat mesenteric rings indepen-
dent of the endothelium. Based on this observation and supported
by the fact that organic nitrates have a history of acting as NO
donors, we investigated a possible involvement of the NO-path-
way in the mechanisms underlying NDBP-induced vasorelaxation.
Based on our ﬁndings showing that hydroxocobalamin
(30 mM) attenuated the vasorelaxation of NDBP (Fig. 4), we
demonstrated that NO plays a role in the vasodilatation induced
by the tested compound. In addition, in the presence of the
soluble guanylate cyclase inhibitor, ODQ, the NDBP-induced
relaxant response was almost abolished (Fig. 4), further suggest-
ing that the vasorelaxation elicited by NDBP involves NO release
and NO/cGMP pathway activation.It has been widely reported that organics nitrates cause
vasorelaxation via activation of the soluble guanylyl cyclase
(sGC) by NO, which in turn dose-dependently increases the levels
of cGMP, demonstrating that NO is the effector molecule released
by the nitrovasodilator, being responsible for causing vasorelaxa-
tion. Furthermore, the accumulation of cGMP leads to activation
of protein kinases such as PKG. Among the downstream effectors
of PKG for vasorelaxation, Kþ channels play an important role in
the regulation of smooth muscle contractility and vascular tone,
being determinant for the homeostasis of blood pressure. On the
other hand, NO can induce vasodilatation by cGMP-independent
mechanism throughout direct action on Kþ channels (Bolotina
et al., 1994; Mistry and Garland, 1998; Plane et al., 1996).
In order to investigate whether NDBP-induced vasodilatation
through the NO release could involve the participation of Kþ
channels, we incubated some preparations with KCl (20 mM), which
promotes partial blockade of Kþ efﬂux, reducing the relaxation
mediated by the opening of Kþ channels (Gurney, 1994). As a result,
increasing the concentration of extracellular Kþ from 4mM to
20 mM signiﬁcantly altered the vasorelaxant response induced by
NDBP and reduced the maximum effect, suggesting that hyperpo-
larizing mechanisms mediated by the opening of Kþ channels are
part of the effect induced by the compound.
Last but not the least, the vasorelaxant responses induced by
increasing concentrations of NDBP (108–104 M) were also
signiﬁcantly rightward shifted, when incubated with tetraethy-
lammonium (TEA, 1 mM), calcium sensitive Kþ channel blocker
(ME¼87.975.8%, Po0.05, n¼6), as illustrated in Fig. 4.
The concentration of TEA employed in our studies (1 mM) is
known for selectively blocking the large conductance Ca2þ-
sensitive Kþ channels (Archer et al., 1994). Previous studies
indicate that NO and NO donors activate these channels by
cGMP-dependent protein kinases, by a direct modulation, or by
combining these two mechanisms (Archer et al., 1994; Bolotina
et al., 1994). In support to our data, several studies have demon-
strated the activation of BKCa by NO or different NO donors in
others vascular tissues, such as pulmonary and cerebral arteries
(Bialecki and Stinson-Fisher, 1995; Hempelmann et al., 2001).
There is controversy if TEA 1 mM is selective for BKCa, therefore
we used charybdotoxin (ChTX, 100 nM), a BKCa blocker, which is
more selective than TEA, and the vasorelaxation remained atte-
nuated, conﬁrming the participation of BKCa in the effect induced
by NDBP.
In addition to the BKCa channels, it has been reported that NO
hyperpolarizes the membrane through the activation of ATP-
sensitive Kþ channels (KATP) in coronary arteries of humans,
causing vasorelaxation (Farouque et al., 2004). In our experi-
ments, after administration of the well known highly selective
ATP-sensitive Kþ channels blocker, glibenclamide, the NDBP-
induced vasodilatation was signiﬁcantly attenuated (Fig. 4), sug-
gesting the involvement of KATP channels in the vasorelaxant
effect produced by the compound. Our data are in accordance to
results reported by Garland and McPherson (1992). However,
Meisheri et al. (1993) reported that glibenclamide did not affect
the relaxation mediated by sodium nitroprusside and NOC-7 in
rat isolated aorta, suggesting that KATP channels do not play a role
in the vasorelaxation mediated by NO donors in aorta. These
divergences could be explained by differences among the NO
donors used, methods employed as well as the vascular tissue
evaluated.
It has been reported that NO also modulate the activity of
voltage-sensitive Kþ channels (Archer et al., 1994). The 4-amino-
pyridine, a selective blocker of these Kþ channels, signiﬁcantly
rightward shifted the curve concentration-response to NDBP
on mesenteric artery rings, conﬁrming the modulation of these
Kþ channels by the NO released from NDBP (Fig. 4). The
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Oate also was attenuated by Kþ channel blocker 4-aminopyridine
(4-AP) in rat basilar arteries (Sampson et al., 2001).
Among those Kþ channels involved in the response mediated by
NDBP, the BKCa and KATP appeared to be the most important ones,
since the blockade with charybdotoxin or glibenclamide, respec-
tively, caused the signiﬁcant effect in attenuating the vasorelaxant
response elicited by the NDBP, being equivalent to the attenuation
produced by the non-selective blockade with KCl (20 mM).
It is important to report that the involvement of Kþ channels
in the NDBP-induced vasorelaxation seems to be, mainly, depen-
dent of soluble guanylate cyclase activation, since the adminis-
tration of ODQ virtually abolished the relaxing effect induced by
the compound. However, residual vasodilatation found in pre-
parations with ODQ alone was reduced when incubated with ODQ
and TEA together, suggesting a direct action of NO in Kþ channels.
Corroborating the functional data, it was observed that the NDBP
presents kinetics of NO release in vascular smooth muscle cells
similar to glyceryl trinitrate (GTN), an organic nitrate widely known
with structure suchlike to NDBP and used in the clinics. Although we
have not tested the vasorelaxation effect induced by glycerin
trynitrate, glycerin was used as a positive control for measuring
NO in vascular smooth muscle cells. A series of elegant studies
performed by Miller et al. (2008) aiming to measure NO release
during GTN-induced relaxation reported that GNT was able to
induce relaxation independent on NO release. However, in that
case, authors may have succeed in measuring GTN-derived NO at
lower doses because NO was very diluted in the organ bath. In our
study, NO was directly measure at cell culture level, been much
more sensitive and precise. We believe that, although the potency of
NDBP was smaller than that reported for GTN, both NDBP and GTN
are able to induce vasodilation via NO production/release. Further-
more, the in vivo implications of NDBP organic nitrate as well as its
ability to induce tolerance are under investigation.5. Conclusion
In summary, here we suggest the NDBP as a new NO generator.
In support of this concept, under our experimental conditions,
NDBP was able to induce relaxation in rat mesenteric rings pre-
constricted with phenylephrine via NO release and activation of
the sGC/cGMP pathway, with participation of Kþ channels. It has
also released NO in vascular smooth muscle cell culture. These
data seem to be exciting, being the NDBP a possible alternative for
cardiovascular diseases treatment; however, several studies
regarding the metabolism of the compound, tolerance and phy-
siological signiﬁcance of the vasorelaxant activity of NDBP awaits
further investigation before it can be used in clinical trials.Acknowledgments
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